A panelist discusses how patients should communicate comprehensively with their care team about symptom patterns, documentation methods, and warning signs of polycythemia vera progression, including ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best ...

Dr Gerds explores similarities and differences in symptomatic patients compared to asymptomatic patients with PV. Aaron Gerds, MD, MS: Certainly patients with polycythemia vera [PV] can present both ...

Q: My friend says his uncle is being treated for a disease where he has too much blood and he gets "bloodletting’" every other day, like in the Middle Ages. Is there really such a thing, or is he ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation can make your body produce too many blood cells.  JAK2 ...

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening ...

The blood you don’t need could be exactly what someone else is praying for. It sounds inconceivable, yet for patients requiring frequent therapeutic phlebotomy—blood removal as treatment—this blood is ...

Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging ...